JP2019524131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524131A5 JP2019524131A5 JP2019507161A JP2019507161A JP2019524131A5 JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5 JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- poxvirus
- nucleic acid
- vaccinia virus
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 21
- 241000700618 Vaccinia virus Species 0.000 claims 19
- 230000001093 anti-cancer Effects 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 7
- 241000283690 Bos taurus Species 0.000 claims 5
- 241000191927 Rabbitpox virus Utrecht Species 0.000 claims 5
- 241000700646 Vaccinia virus WR Species 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000700635 Orf virus Species 0.000 claims 3
- 108700039887 Essential Genes Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 108010013351 sodium-iodide symporter Proteins 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022017693A JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372408P | 2016-08-09 | 2016-08-09 | |
| US62/372,408 | 2016-08-09 | ||
| US201762519010P | 2017-06-13 | 2017-06-13 | |
| US62/519,010 | 2017-06-13 | ||
| PCT/US2017/046163 WO2018031694A1 (en) | 2016-08-09 | 2017-08-09 | Chimeric poxvirus compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022017693A Division JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524131A JP2019524131A (ja) | 2019-09-05 |
| JP2019524131A5 true JP2019524131A5 (enExample) | 2020-09-17 |
| JP7023929B2 JP7023929B2 (ja) | 2022-02-22 |
Family
ID=61163330
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507161A Active JP7023929B2 (ja) | 2016-08-09 | 2017-08-09 | キメラポックスウイルス組成物及びその使用 |
| JP2022017693A Active JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A Active JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A Pending JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022017693A Active JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A Active JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A Pending JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12084687B2 (enExample) |
| EP (1) | EP3497209A4 (enExample) |
| JP (4) | JP7023929B2 (enExample) |
| KR (3) | KR102557818B1 (enExample) |
| CN (3) | CN118853594A (enExample) |
| AU (2) | AU2017311380A1 (enExample) |
| BR (1) | BR112019002646A2 (enExample) |
| CA (1) | CA3033512A1 (enExample) |
| MX (1) | MX2019001672A (enExample) |
| RU (2) | RU2757002C2 (enExample) |
| WO (1) | WO2018031694A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN118853594A (zh) * | 2016-08-09 | 2024-10-29 | 希望之城 | 嵌合痘病毒组合物及其用途 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3664841A1 (en) * | 2017-08-11 | 2020-06-17 | City of Hope | Oncolytic virus expressing a car t cell target and uses thereof |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| MX2020009262A (es) * | 2018-03-07 | 2021-01-08 | Transgene | Vectores de parapoxvirus. |
| WO2019213173A1 (en) * | 2018-04-30 | 2019-11-07 | City Of Hope | Neural stem cell compositions including chimeric poxviruses for cancer treatment |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| WO2023213763A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CN120380015A (zh) | 2022-08-18 | 2025-07-25 | 特兰斯吉恩公司 | 嵌合痘病毒 |
| AU2024280931A1 (en) * | 2023-05-26 | 2025-11-27 | Probiogen Ag | Rapid selection system for the generation of recombinant enveloped viruses |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| CN120718864B (zh) * | 2025-08-28 | 2025-11-28 | 山东农业大学 | 一种高度不成熟鸭坦布苏病毒及其培养方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406376B (de) * | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| US7067251B2 (en) | 2000-03-28 | 2006-06-27 | University Of Rochester | Methods of directly selecting cells expressing inserts of interest |
| DE60314541T2 (de) * | 2002-11-25 | 2008-02-28 | Bavarian Nordic A/S | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
| SG179291A1 (en) * | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| CA2705873C (en) * | 2007-11-19 | 2012-06-12 | Philippe Erbs | Poxviral oncolytic vectors |
| CA2795695A1 (en) | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
| WO2012142529A2 (en) | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| CN104768567B (zh) | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CN118853594A (zh) * | 2016-08-09 | 2024-10-29 | 希望之城 | 嵌合痘病毒组合物及其用途 |
-
2017
- 2017-08-09 CN CN202410528631.4A patent/CN118853594A/zh active Pending
- 2017-08-09 KR KR1020197006987A patent/KR102557818B1/ko active Active
- 2017-08-09 MX MX2019001672A patent/MX2019001672A/es unknown
- 2017-08-09 WO PCT/US2017/046163 patent/WO2018031694A1/en not_active Ceased
- 2017-08-09 BR BR112019002646-0A patent/BR112019002646A2/pt active IP Right Grant
- 2017-08-09 RU RU2019106319A patent/RU2757002C2/ru active
- 2017-08-09 CN CN202410528486.XA patent/CN118834840A/zh active Pending
- 2017-08-09 EP EP17840232.7A patent/EP3497209A4/en active Pending
- 2017-08-09 KR KR1020257014373A patent/KR20250067190A/ko active Pending
- 2017-08-09 CN CN201780062335.8A patent/CN110199018B/zh active Active
- 2017-08-09 RU RU2021128158A patent/RU2021128158A/ru unknown
- 2017-08-09 JP JP2019507161A patent/JP7023929B2/ja active Active
- 2017-08-09 KR KR1020237024342A patent/KR20230113832A/ko not_active Ceased
- 2017-08-09 CA CA3033512A patent/CA3033512A1/en active Pending
- 2017-08-09 US US16/324,541 patent/US12084687B2/en active Active
- 2017-08-09 AU AU2017311380A patent/AU2017311380A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017693A patent/JP7395628B2/ja active Active
-
2023
- 2023-11-20 AU AU2023270200A patent/AU2023270200A1/en active Pending
- 2023-11-28 JP JP2023200433A patent/JP7631485B2/ja active Active
-
2024
- 2024-07-17 US US18/776,109 patent/US20250084384A1/en active Pending
-
2025
- 2025-02-04 JP JP2025016649A patent/JP2025072482A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524131A5 (enExample) | ||
| JP2022065034A5 (enExample) | ||
| JP2025072482A5 (enExample) | ||
| JP2024026191A5 (enExample) | ||
| RU2019106319A (ru) | Композиции химерного поксвируса и их применение | |
| JP2015533841A5 (enExample) | ||
| RU2022103603A (ru) | Направляемые нуклеиновыми кислотами нуклеазы | |
| Kaynarcalidan et al. | Vaccinia virus: from crude smallpox vaccines to elaborate viral vector vaccine design | |
| JP2012509340A5 (enExample) | ||
| Mizuno et al. | Novel haloarchaeal viruses from Lake Retba infecting Haloferax and Halorubrum species | |
| JP2013507935A5 (enExample) | ||
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| JP2015533297A5 (enExample) | ||
| JP2011155981A5 (enExample) | ||
| JP2017524348A5 (enExample) | ||
| Stik et al. | The oncogenic microRNA OncomiR-21 overexpressed during Marek's disease lymphomagenesis is transactivated by the viral oncoprotein Meq | |
| CN110944675A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| Murata et al. | Characterization of Meq proteins from field isolates of Marek’s disease virus in Japan | |
| JP2015533791A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| JP2013538554A5 (enExample) | ||
| JP2019500907A5 (enExample) | ||
| MX2024002641A (es) | Uso de micro ácido ribonucleico (arn) para la regulación por disminución de la expresión de transgenes citotóxicos mediante el virus vaccinia ankara modificado (mva). | |
| Chen et al. | Molecular evidence and sequence analysis of a natural reassortant between Cucumber mosaic virus subgroup IA and II strains |